NEKTAR THERAPEUTICS (NKTR): Nasdaq/NYSE listing notice — Nektar gets Nasdaq bid-price extension to May 2024; stock moves to Capital Market

NEKTAR THERAPEUTICS

Nasdaq granted additional 180-day period until May 20, 2024 to regain $1.00 minimum bid price.
Common stock will transfer from Nasdaq Global Select to Nasdaq Capital Market on Nov 28, 2023.
Company intends to cure deficiency via reverse stock split if needed before May 20, 2024.
If compliance not regained, Nasdaq may delist NKTR; company can appeal to a Listing Qualifications panel.
Stock continues to trade under symbol NKTR on the Nasdaq Capital Market.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

NEKTAR THERAPEUTICS received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

November 24, 2023, the Company received a written notice (the “Notice”) from Nasdaq stating that the Company is eligible for an additional 180 calendar day period, or until May 20, 2024, to regain compliance with the minimum bid price requirement. In the Notice, Nasdaq noted that the Company’s common stock had not regained compliance with the minimum bid price requirement during the initial 180 calendar day period that ended on November 22, 2023, and that the Company had submitted written notice to Nasdaq of its intention to cure the required minimum bid price deficiency by effecting a reverse

View on SEC.gov

2 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

NEKTAR THERAPEUTICS filing history →

Source: SEC EDGAR

accession 0001213900-23-090252

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.